AgeX Therapeutics Inc (AGE)

Overview

AgeX Therapeutics, Inc., a pioneering biotechnology firm with a focus on developing innovative therapies aimed at human aging and degenerative diseases, marked a significant milestone in its history as of March 26, 2024, when it was acquired by Serina Therapeutics, Inc., through a reverse merger transaction. Situated in Alameda, California, and founded in 2017, AgeX has been at the forefront of exploring the potential of novel therapeutics. Their ambitious scientific endeavors encompass a wide array of treatments designed to combat the complexities of aging and associated conditions, leveraging cutting-edge research and collaborative efforts, notably with the University of California at Irvine, to push the boundaries of cellular therapies targeting neurological disorders and diseases.

Products and Services

• AGEX-BAT1

A groundbreaking cell therapy product candidate, AGEX-BAT1 is in development to address a spectrum of age-related metabolic disorders, including Type II adult-onset diabetes and obesity. This innovative treatment encapsulates AgeX's commitment to combating the burdens of aging through therapeutic intervention.

• AGEX-VASC1

AGEX-VASC1 represents a cutting-edge cell-based therapeutic approach aimed at revitalizing vascular support in aged ischemic tissues. Target conditions include peripheral vascular disease and ischemic heart disease, with the therapy poised to offer new hope in restoring circulatory health and functionality.

• AGEX-iTR1547

In the realm of discovery, AGEX-iTR1547 stands out as a leader among small molecule drug-based therapeutic candidates, focusing on the ambitious goal of achieving scarless wound repair. This drug-based formulation embodies AgeX’s innovative strategy towards engaging the body’s healing processes with precision and efficiency.

• AGEX-iTR1550 (Renelon)

As AgeX's leading biologic candidate for induced tissue regeneration, AGEX-iTR1550 (Renelon) heralds a new era in gene delivery technology. This cutting-edge solution showcases the company's dedication to unlocking the regenerative potential of the human body, setting a new standard for therapeutic innovation in the process.